Drug
Pirtobrutinib clinical trials
Also written LOXO-305, LY3527727 and Jaypirca.
- studies test it
- 64
- open now
- 38
- in phase 3
- 7
- first study started
- 2020
Keep track of what changes. Save the pirtobrutinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Brand
- Jaypirca
- 11
Studies by the year they started
64 studies that test it; most in 2025 (17)
| Year | Studies |
|---|---|
| 2020 | 8 |
| 2021 | 10 |
| 2022 | 4 |
| 2023 | 4 |
| 2024 | 7 |
| 2025 | 17 |
| 2026 | 14 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 17
- Phase 2
- 38
- Phase 3
- 7
- Phase 4
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 29 · Other 35
Eli Lilly and Company (17) · Loxo Oncology, Inc. (10) · M.D. Anderson Cancer Center (6) · University of Utah (2) · Changzhou No.2 People's Hospital (2) · Dana-Farber Cancer Institute (1) · Mayo Clinic (1) · Institute of Hematology & Blood Diseases Hospital, China (1)
Often tested with
Tested in the same studies.
Venetoclax (9) · Rituximab (8) · Lisaftoclax (3) · Obinutuzumab (3) · Mosunetuzumab (2) · Polatuzumab vedotin (2) · Glofitamab (2) · Sintilimab (2)
Studies
Open first, then newest update. How each study uses pirtobrutinib is read from its arms, and is right about nine times in ten.
Testing it · 64
- Immune Profiling of CLL/SLL Treated With First-Line PirtobrutinibRecruitingEarly Phase 1National Heart, Lung, and Blood Institute (NHLBI)NCT07428707Written as Pirtobrutinib
- Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's TransformationRecruitingPhase 2Christine RyanNCT06043674Written as Pirtobrutinib
- Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID TrialRecruitingPhase 3SWOG Cancer Research NetworkNCT07220187Written as Pirtobrutinib
- A Study of Pirtobrutinib in Participants With Immune ThrombocytopeniaRecruitingPhase 1/2Eli Lilly and CompanyNCT06721013Written as Pirtobrutinib
- Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell LymphomaRecruitingPhase 2University of California, San FranciscoNCT06252675Written as Pirtobrutinib
- A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)RecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07231952Written as Pirtobrutinib
- Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic LeukemiaRecruitingPhase 2Jennifer WoyachNCT07685717Written as Pirtobrutinib
- Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)Not yet recruitingPhase 2University of UtahNCT07548450Written as Pirtobrutinib
- Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCLRecruitingPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT06553872Written as Pirtobrutinib
- A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecruitingPhase 4Eli Lilly and CompanyNCT07218341Written as Pirtobrutinib
- Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLLNot yet recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07831395Written as Pirtobrutinib
- Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With ZanubrutinibRecruitingPhase 2Peter MacCallum Cancer Centre, AustraliaNCT06812715Written as Pirtobrutinib
- Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLLRecruitingPhase 3Nurix Therapeutics, Inc.NCT07516093Written as Pirtobrutinib
- A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)RecruitingPhase 3Loxo Oncology, Inc.NCT05254743Written as Pirtobrutinib
- Pirtobrutinib + R-CHOP for Untreated Non-GCB DLBCLNot yet recruitingPhase 2Changzhou No.2 People's HospitalNCT07744737Written as Pirtobrutinib plus R-CHOP
- Pirtobrutinib+Pola-R-CHP for Newly Diagnosed Non-GCB DLBCLNot yet recruitingPhase 2Changzhou No.2 People's HospitalNCT07744724Written as Pirtobrutinib+Pola-R-CHP
- LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell MalignanciesRecruitingPhase 1Medical College of WisconsinNCT05990465Written as Pirtobrutinib
- Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).RecruitingPhase 2M.D. Anderson Cancer CenterNCT06967610Written as Pirtobrutinib
- Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted TherapyNot yet recruitingPhase 2Henan Cancer HospitalNCT07684950Written as Pirtobrutinib
- Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL TrialRecruitingPhase 2University of WashingtonNCT06948786Written as Pirtobrutinib
See all 64 studies that test pirtobrutinib →
Given in every arm · 4 — pirtobrutinib is usual care beside what is tested
- Mosunetuzumab for CLL MRD ClearanceRecruitingPhase 1/2Inhye AhnNCT07052695Written as Pirtobrutinib
- Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's SyndromeActive, not recruitingPhase 1/2GenmabNCT04623541Written as Pirtobrutinib
- Study of Oral LOXO-338 in Patients With Advanced Blood CancersCompletedPhase 1Eli Lilly and CompanyNCT05024045Written as Pirtobrutinib
- A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHLCompletedPhase 1/2Loxo Oncology, Inc.NCT03740529Written as Pirtobrutinib
As the comparator · 3 — what is tested is compared with pirtobrutinib
- A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaRecruitingPhase 3BeOne MedicinesNCT06973187Written as Pirtobrutinib
- A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).Not yet recruitingPhase 3Beijing InnoCare Pharma Tech Co., Ltd.NCT07784101Written as Pirtobrutinib
- ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLLRecruitingPhase 3Newave Pharmaceutical IncNCT07342478Written as Pirtobrutinib
Codes
What other systems call pirtobrutinib · ClinicalTrials.gg INT001935
- MeSH (NLM) C000723100pirtobrutinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) JNA39I7ZVBPIRTOBRUTINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q116622551pirtobrutinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C158617PirtobrutinibOne source FDA
- DrugBank DB17472One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000723100 | pirtobrutinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | JNA39I7ZVB | PIRTOBRUTINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q116622551 | pirtobrutinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C158617 | Pirtobrutinib | One source FDA |
| DrugBank | DB17472 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.